secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiromic Biopharma, Inc. (—)
CIK:        0001792581
Form:       8-K
Filed at:   2022-11-30T23:59:59+00:00
Accession:  0001558370-22-018277
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiromic BioPharma receives Nasdaq delisting notice for stockholders' equity deficiency
--------------------------------------------------------------------------------

- Nasdaq letter dated Nov 23, 2022: stockholders' equity $284,100 vs required $2.5M.
- Also failed alternative standards: market value of listed securities ≥$35M or net income $500K.
- Company has 45 days (by Jan 9, 2023) to submit a compliance plan; extension up to 180 days possible.
- Common stock continues trading on Nasdaq under KRBP but subject to compliance.
- Company seeking financing to regain compliance; no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1792581/000155837022018277/0001558370-22-018277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1792581/000155837022018277/krbp-20221123x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-018277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer